Overview

Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
0
Participant gender:
All
Summary
This is a long-term observational study of patients that were treated with at least 1 dose of study treatment (plerixafor or placebo) in the AMD3100-3102 protocol (NCT00103662).
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
JM 3100
Lenograstim
Plerixafor
Sargramostim
Criteria
Inclusion Criteria:

- All patients who received a dose of study treatment (plerixafor or placebo) in
protocol AMD3100-3102 (NCT00103662)

Exclusion Criteria:

- No Exclusion Criteria